伴有EGFR外显子19缺失且转移至胃肠道的肺鳞状细胞癌
Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion.
作者信息
Weiss Glen J, Liman Agnes K, Allen Jeffrey, Cheung Philip Y, Kukunoor Rajesh N
机构信息
Cancer Treatment Centers of America, Goodyear, AZ 85338, USA ; The Translational Genomics Research Institute, Phoenix, AZ 85004, USA ; CRAB Clinical Trials Consortium, Seattle, WA 98101, USA.
出版信息
Case Rep Med. 2013;2013:874836. doi: 10.1155/2013/874836. Epub 2013 Sep 19.
Abstract
We describe three confirmed cases of squamous cell carcinoma (SCC) of the lung with metastasis to the gastrointestinal (GI) tract, with two having epidermal growth factor receptor (EGFR) exon 19 deletions in all available specimens. One of these patients received EGFR tyrosine kinase directed therapy for a brief period with some symptom relief. Consideration of EGFR exon 19 mutation testing in SCC of the lung, particularly for those with GI tract metastasis, may identify this potentially drug-targetable entity.
摘要
我们描述了3例确诊的肺鳞状细胞癌（SCC）转移至胃肠道（GI）的病例，其中2例在所有可用标本中均存在表皮生长因子受体（EGFR）外显子19缺失。这些患者中有1例接受了短期的EGFR酪氨酸激酶定向治疗，症状有所缓解。对于肺SCC，尤其是那些伴有胃肠道转移的患者，考虑进行EGFR外显子19突变检测，可能会识别出这种具有潜在药物可靶向性的实体。
相似文献
1
Squamous Cell Carcinoma of the Lung with Metastasis to the GI Tract Associated with EGFR Exon 19 Deletion.
Case Rep Med. 2013;2013:874836. doi: 10.1155/2013/874836. Epub 2013 Sep 19.
2
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29.
3
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
J Oncol Pharm Pract. 2016 Jun;22(3):461-76. doi: 10.1177/1078155215577810. Epub 2015 Apr 8.
4
EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma.
Onco Targets Ther. 2017 Sep 18;10:4607-4613. doi: 10.2147/OTT.S130051. eCollection 2017.
5
EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
Mol Med Rep. 2018 Jun;17(6):7575-7584. doi: 10.3892/mmr.2018.8859. Epub 2018 Apr 5.
6
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.
Clin Lung Cancer. 2016 Jul;17(4):309-14. doi: 10.1016/j.cllc.2015.11.009. Epub 2015 Dec 1.
7
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Eur J Cancer. 2019 Sep;119:77-86. doi: 10.1016/j.ejca.2019.06.025. Epub 2019 Aug 16.
8
Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.
9
Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
J Thorac Oncol. 2013 Sep;8(9):1148-55. doi: 10.1097/JTO.0b013e31829f684a.
10
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
J Thorac Oncol. 2013 Jan;8(1):89-95. doi: 10.1097/JTO.0b013e31827690b5.
引用本文的文献
1
A Case of Primary Lung Adenocarcinoma With Metastasis to Colon Harboring EGFR Exon 19 Deletion.
Cureus. 2024 Jul 2;16(7):e63665. doi: 10.7759/cureus.63665. eCollection 2024 Jul.
2
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.
Oncotarget. 2017 Feb 25;8(32):53675-53683. doi: 10.18632/oncotarget.15726. eCollection 2017 Aug 8.
3
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Oncotarget. 2017 Jul 25;8(30):49680-49688. doi: 10.18632/oncotarget.17915.
4
Progression inference for somatic mutations in cancer.
Heliyon. 2017 Apr 11;3(4):e00277. doi: 10.1016/j.heliyon.2017.e00277. eCollection 2017 Apr.
5
Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.
Oncol Lett. 2014 Sep;8(3):1039-1042. doi: 10.3892/ol.2014.2321. Epub 2014 Jul 4.
本文引用的文献
1
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5.
2
Gastrointestinal metastasis from primary lung cancer: CT findings and clinicopathologic features.
AJR Am J Roentgenol. 2009 Sep;193(3):W197-201. doi: 10.2214/AJR.08.1907.
3
Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan.
J Clin Oncol. 2006 Oct 20;24(30):4939-40. doi: 10.1200/JCO.2006.06.3354.
4
Gastro-intestinal metastasis of primary lung carcinoma: clinical presentations and outcome.
Lung Cancer. 2006 Dec;54(3):319-23. doi: 10.1016/j.lungcan.2006.08.007. Epub 2006 Sep 27.
5
Colonic metastases from primary squamous cell carcinoma of the lung.
Eur J Cardiothorac Surg. 2001 May;19(5):719-20. doi: 10.1016/s1010-7940(01)00646-7.
Zotero 插件